Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-27
2006-06-27
Russe, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021800, C530S308000, C530S324000, C530S345000
Reexamination Certificate
active
07067488
ABSTRACT:
The present invention relates to a GLP-1 peptide having the following formula, or a pharmaceutically acceptable salt thereof:in-line-formulae description="In-line Formulae" end="lead"?X-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-lle-Ala-Trp-Leu-val-Lys-Gly-Arg-Y (SEQ ID NO. 1)in-line-formulae description="In-line Formulae" end="tail"?wherein X is a rigidifying hydrophobic moiety and wherein Y is selected from the group consisting of OH, NH2and Gly-OH. Moreover, the present invention relates to pharmaceutical compositions comprising a therapeutically effective amount of a peptide of the present invention, or a pharmaceutically acceptable salt thereof, in association with at least one constituent selected from a pharmaceutically acceptable carrier, diluent, and excipient.
REFERENCES:
patent: 5512549 (1996-04-01), Chen et al.
patent: 5545618 (1996-08-01), Buckley et al.
patent: 2004/0018981 (2004-01-01), Dong
patent: 0 733 644 (1996-09-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO 99/43707 (1999-09-01), None
patent: WO 00/55119 (2000-09-01), None
patent: WO 02/10195 (2002-02-01), None
Adelhorst et al:, “Structure-activity sutides of glucagon-like peptide-1,”J. Biol. Chem., 269(9):6275-6278, 1994.
Burcelin et al., “Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analogy of glucagon-like peptide-1,”Metabolism, 48(2):252-258, 1999.
D'alessio et al., “Glucagon-like peptide 1 decreases hepatic glucose production independent of insulin and glucagon,”Diabetes, 46(suppl 1):29A, 1997.
Deacon et al., “Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity,”Diabetologia, 41:271-278, 1998.
Doyle and Egan, “Glucagon-like peptide-1,”Recent Prog. Horm. Res., 56:377-399, 2001.
Doyle et al., “Insertion of an N-Terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent,”Endocrinology, 142(10):4462-4468, 2001.
Drucker, “Minireview: the glucagon-like peptides,”Endocrinology, 142(2):521-527, 2001.
Dugas and Penney, In:Bioorganic Chemistry, Springer-Verlag, NY, 54-92, 1981.
Gorrell et al., “CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes,”Scand. J. Immunol., 54:249-264, 2001.
Gutniak et al., “Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus,”The New England Journal of Medicine, 326:1316-1322, 1992.
Gutniak, “Treatment of diabetes GLP-1: a new kid in town,”International Diabetes Monitor, 9(2):1-12, 1997.
Holst, “Glucagonlike peptide 1: a newly discovered gastrointestinal hormone,”Gastroenterology, 107:1848-1855, 1994.
Holst, “Glucagon-like peptide 1 (GLP-1: an intestinal hormone, signaling nutritional abundance, with an unusual therapeutic potential,”Trends Endocrinol. Metab., 10(6):229-235, 1999.
Holz et al., “Activation of a cAMP-regulated Ca+2 signaling pathway in pancreatic β-cells by the insulinotropic hormone glucagon-like peptide-1,”J. Biol. Chem., 270(30):17749-17757, 1995.
Kieffer and Habener, “The glucagon-like peptides,”Endocrine Reviews, 20(6):876-913, 1999.
Kreymann et al., “Glucagon-like peptide-1 7-36: a physiological incretin in man,”Lancet, 2(8571):1300:1304, 1987.
Merrifield, “Solid phase peptide synthesis. I. The synthesis of a tetrapeptide,”Chem. Soc., 85:2149-2154, 1962.
Nauck et al., “Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes,”Diabetoligia, 29:46-52, 1986.
Nauck et al., “Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1(7-36 amide) in type 2 (non-insulin-dependent) diabetic patients,”Diabetologia, 36:741-744, 1993.
Nauck, “Glucagonlike peptide 1,”Curr. Opin. Endocrinol. Diabet., 4:291-299, 1997.
Peptide synthesis protocols, Methods in molecular biology, vol. 35, Pennington and Dunn (eds.), Humana Press, 1994.
Perfetti and Merkel, “Glucagon-like peptide-1: a major regulator of pancreatic β-cell function,”European Journal of Endocrinology, 143:717-725, 2000.
Remington's Pharmaceutical Sciences, 15thed., 33:624-652, Mack Publishing Company, Easton, PA, 1980.
Scrocchi et al., “Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene,”Nature Medicine, 2(11):1254-1258, 1996.
Siegel et al., “Biological activity of GLP-1-analogues with N-terminal modifications,”Regulatory Peptides, 79:93-102, 1999.
Stewart and Young, In:Solid Phase Peptide Synthesis, 24-66, Freeman, San Francisco, 1969.
Suzuki et al., “Effects of GLP-1 and its fragment peptides on pancreatic hormone release,”Diabetes Res., 5(Suppl 1):S30, 1988.
Toft-Nielsen et al., “Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients,”Diabetes Care, 22:1137-1143, 1999.
Tolessa et al., “Inhibitory effect of glucagon-like peptide-1 on small bowl motility,”J. Clin. Invest., 102(4):764-774, 1998.
Wang et al., “Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats,”J. Clin. Invest., 99(12):2883-2889, 1997.
Xiao et al., “Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo,”Biochemistry, 40:2860-2869, 2001.
Xu et al., “Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased βcell mass and improved glucose tolerance in diabetic rats,”Diabetes, 48:2270-2276, 1999.
Abribat Thierry
Gravel Denis
Habi Abdelkrim
Peri Krishna
Fulbright & Jaworski
Russe Jeffrey Edwin
TheraTechnologies Inc.
LandOfFree
Modified GLP-1 peptides with increased biological potency does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified GLP-1 peptides with increased biological potency, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified GLP-1 peptides with increased biological potency will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3696053